Credit-note turnover adjustments preserve inverted-duty refunds, while ministerial re-computation does not constitute an impermissible appellate reman...
Revisional jurisdiction over export quota premium deductions requires both error and Revenue prejudice; a permissible assessment view cannot be displa...
Page of 4881
Press 'Enter' after typing page number.
501 to 520 of 97618 Results
❮
❯
❯❯
0 / 200
Expand Note
Add to Folder
No Folders have been created
+
Are you sure you want to delete "My most important" ?
Bulk drugs and active pharmaceutical ingredients qualify as drugs and medicines where they meet the applicable pharmaceutical definitions, even when imported for examination, testing, clinical research, bioavailability or bioequivalence studies. The description-based IGST rate entry covering drugs and medicines under any chapter applies to qualifying APIs, provided they do not fall within the specified nil-rate exclusion. The entry is not restricted to finished formulations under Chapter 30. Where APIs are chemically classifiable under Chapters 28 or 29, the specific drug entry prevails over the general inorganic or organic chemical entries. Qualifying goods are therefore chargeable at 5 per cent IGST.
Bulk drugs and active pharmaceutical ingredients qualify as drugs and medicines where they meet the applicable pharmaceutical definitions, even when imported for examination, testing, clinical research, bioavailability or bioequivalence studies. The description-based IGST rate entry covering drugs and medicines under any chapter applies to qualifying APIs, provided they do not fall within the specified nil-rate exclusion. The entry is not restricted to finished formulations under Chapter 30. Where APIs are chemically classifiable under Chapters 28 or 29, the specific drug entry prevails over the general inorganic or organic chemical entries. Qualifying goods are therefore chargeable at 5 per cent IGST.
Note: It is a system-generated summary and is for quick reference only.
TaxTMI 
TaxTMI 
of 4881 
